利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

29 条记录 (耗时 0.018 秒)

    ADIPONECTIN EXPRESSION-INDUCING AGENTS AND USES THEREOF
    3.
    发明申请
    ADIPONECTIN EXPRESSION-INDUCING AGENTS AND USES THEREOF 审中-公开
    ADIPONECTIN表达诱导剂及其用途

    公开(公告)号：US20100273708A1

    公开(公告)日：2010-10-28

    申请号：US12762437

    申请日：2010-04-19

    申请人： Takashi KADOWAKI ,  Toshimasa Yamauchi ,  Shoko Kitajima ,  Yusuke Ito

    发明人： Takashi KADOWAKI ,  Toshimasa Yamauchi ,  Shoko Kitajima ,  Yusuke Ito

    IPC分类号： A61K38/17 ,  A61P3/00

    CPC分类号： C07K14/47 ,  A61K38/00 ,  A61K48/00 ,  G01N33/6875 ,  G01N33/74 ,  G01N33/92 ,  G01N2500/10 ,  G01N2800/044

    摘要： The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents. KLF9, which can bind to the 32-bp fragment of position −188 to position −157 from the adiponectin expression start site, was demonstrated to enhance adiponectin promoter activity. Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases.

    摘要翻译： 本发明提供了脂联素表达诱导剂和使用其的治疗剂用于肥胖症和肥胖相关疾病如心血管疾病或代谢疾病，以及搜索脂联素表达诱导剂的方法。 KLF9可以结合位点-188的32-bp片段，从脂联素表达起始位点到位置-157，证明增强脂连蛋白启动子活性。 因此，本发明使用KLF9作为脂联素表达诱导剂，并且表明KLF9补充疗法可用于预防和/或治疗肥胖症或肥胖相关疾病，包括诸如胰岛素抵抗和II型糖尿病等代谢疾病和心血管疾病 。

    METHOD OF SELECTIVELY ASSAYING ADIPONECTIN MULTIMERS
    4.
    发明申请
    METHOD OF SELECTIVELY ASSAYING ADIPONECTIN MULTIMERS 有权
    选择ADIPONECTIN多聚体的方法

    公开(公告)号：US20090291461A1

    公开(公告)日：2009-11-26

    申请号：US12468440

    申请日：2009-05-19

    申请人： Hiroyuki EBINUMA ,  Hirokazu Yago ,  Yuka Akimoto ,  Osamu Miyazaki ,  Takashi Kadowaki ,  Toshimasa Yamauchi ,  Kazuo Hara

    发明人： Hiroyuki EBINUMA ,  Hirokazu Yago ,  Yuka Akimoto ,  Osamu Miyazaki ,  Takashi Kadowaki ,  Toshimasa Yamauchi ,  Kazuo Hara

    IPC分类号： G01N33/53

    CPC分类号： G01N33/74 ,  G01N2800/042 ,  G01N2800/32

    摘要： Kits and methods for selectively assaying a target adiponectin multimer in a biological sample. Such methods accurately evaluate the relationship between a disease and adiponectin through selective assay of adiponectin multimers and provide information that cannot be obtained through measurement of the total amount of adiponectin alone. A method for selectively assaying a target adiponectin multimer in a biological sample comprising distinguishing target adiponectin multimer from the other adiponectin multimers by using a protease and/or an antibody.

    摘要翻译： 用于选择性测定生物样品中目标脂联素多聚体的试剂盒和方法。 这种方法通过脂联素多聚体的选择性测定来准确地评估疾病与脂联素之间的关系，并提供通过单独测量脂连蛋白的总量不能获得的信息。 一种用于选择性测定生物样品中的目标脂联素多聚体的方法，包括通过使用蛋白酶和/或抗体将目标脂连蛋白多聚体与其它脂联素多聚体区分开。

    ADIPONECTIN RECEPTOR AND GENE ENCODING THE SAME
    5.
    发明申请
    ADIPONECTIN RECEPTOR AND GENE ENCODING THE SAME 有权
    ADIPONECTIN受体和编码其的基因

    公开(公告)号：US20120027760A1

    公开(公告)日：2012-02-02

    申请号：US13153017

    申请日：2011-06-03

    申请人： Takashi KADOWAKI ,  Toshimasa Yamauchi ,  Ryozo Nagai ,  Junji Kamon

    发明人： Takashi KADOWAKI ,  Toshimasa Yamauchi ,  Ryozo Nagai ,  Junji Kamon

    IPC分类号： C07K16/18 ,  A61K39/395 ,  C12N5/12

    CPC分类号： C07K14/72 ,  Y10S435/81

    摘要： The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.

    摘要翻译： 目的是分离和鉴定人和小鼠脂联素受体，以提供具有脂联素结合能力的新型蛋白质，并提供使用这种蛋白质的脂联素受体的配体，激动剂和拮抗剂的筛选方法和筛选试剂盒。 为了实现这个目的，使用蛋白质作为具有脂联素结合能力的新型蛋白质，即（a）包含根据Seq的氨基酸序列的蛋白质。 No.2,4,6或8，或（b）包含根据Seq的氨基酸序列的蛋白质。 具有一个或多个缺失，替换或添加的氨基酸并具有脂联素结合能力的2,4,6或8号。

    Adiponectin expression-inducing agents and uses thereof
    6.
    发明授权
    Adiponectin expression-inducing agents and uses thereof 失效
    脂联素表达诱导剂及其用途

    公开(公告)号：US07741080B2

    公开(公告)日：2010-06-22

    申请号：US10594969

    申请日：2005-03-31

    申请人： Takashi Kadowaki ,  Toshimasa Yamauchi ,  Shoko Kitajima ,  Yusuke Ito

    发明人： Takashi Kadowaki ,  Toshimasa Yamauchi ,  Shoko Kitajima ,  Yusuke Ito

    IPC分类号： C12P19/34 ,  C12N15/00 ,  C07H21/04

    CPC分类号： C07K14/47 ,  A61K38/00 ,  A61K48/00 ,  G01N33/6875 ,  G01N33/74 ,  G01N33/92 ,  G01N2500/10 ,  G01N2800/044

    摘要： The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents.KLF9, which can bind to the 32-bp fragment of position −188 to position −157 from the adiponectin expression start site, was demonstrated to enhance adiponectin promoter activity. Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases.

    摘要翻译： 本发明提供了脂联素表达诱导剂和使用其的治疗剂用于肥胖症和肥胖相关疾病如心血管疾病或代谢疾病，以及搜索脂联素表达诱导剂的方法。 KLF9可以结合位点-188的32-bp片段，从脂联素表达起始位点到位置-157，证明增强脂连蛋白启动子活性。 因此，本发明使用KLF9作为脂联素表达诱导剂，并且表明KLF9补充疗法可用于预防和/或治疗肥胖症或肥胖相关疾病，包括诸如胰岛素抵抗和II型糖尿病等代谢疾病和心血管疾病 。

    Agents for Regulating Adiponectin Receptor Expression
    8.
    发明申请
    Agents for Regulating Adiponectin Receptor Expression 审中-公开
    调节脂联素受体表达的药剂

    公开(公告)号：US20070238649A1

    公开(公告)日：2007-10-11

    申请号：US10591490

    申请日：2005-03-04

    申请人： Takashi Kadowaki ,  Toshimasa Yamauchi

    发明人： Takashi Kadowaki ,  Toshimasa Yamauchi

    IPC分类号： A61K38/28 ,  A61P3/04 ,  A61P3/08 ,  A61P7/00 ,  A61P9/10 ,  C12N5/06 ,  C12N5/08 ,  C12Q1/18 ,  C12Q1/48

    CPC分类号： A61K38/28 ,  A01K67/027 ,  A01K2267/0362 ,  A61K31/4353 ,  A61K38/1709 ,  G01N33/74 ,  G01N2333/72

    摘要： The present inventors revealed by using fasted and refed mice, that AdipoR1/R2 is a regulator of metabolic sensitivity to nutritional conditions and insulin. They showed that mRNA level of AdipoR1/R2 increased by STZ treatment, and that this increase was restored by insulin. The present inventors confirmed in vitro that insulin reduces AdipoR1/R2 mRNAs in myocytes and such. It was also confirmed that in insulin-resistant models, the AdipoR1/R2 expression was downregulated, and that AMP kinase activation by adiponectin was decreased. The present inventors discovered by using insulin signaling pathway inhibitors, that the downregulation of adiponectin receptors by insulin was mediated by the PI3-kinase/Foxo1 pathway.

    摘要翻译： 本发明人通过使用禁食和重新给予的小鼠显露，AdipoR1 / R2是对营养条件和胰岛素的代谢敏感性的调节剂。 他们表明，通过STZ治疗，AdipoR1 / R2的mRNA水平升高，胰​​岛素恢复增加。 本发明人体外证实了胰岛素能减少肌细胞等中的AdipoR1 / R2mRNA。 还证实在胰岛素抵抗模型中，AdipoR1 / R2表达下调，并且脂联素的AMP激酶活化降低。 本发明人通过使用胰岛素信号通路抑制剂发现，胰岛素对脂联素受体的下调是由PI3激酶/ Foxo1途径介导的。

    Method of selectively assaying adiponectin multimers
    9.
    发明申请
    Method of selectively assaying adiponectin multimers 有权
    选择性测定脂连蛋白多聚体的方法

    公开(公告)号：US20070042424A1

    公开(公告)日：2007-02-22

    申请号：US10575931

    申请日：2004-10-15

    申请人： Hiroyuki Ebinuma ,  Hirokazu Yago ,  Yuka Akimoto ,  Osamu Miyazaki ,  Takashi Kadowaki ,  Toshimasa Yamauchi ,  Kazuo Hara

    发明人： Hiroyuki Ebinuma ,  Hirokazu Yago ,  Yuka Akimoto ,  Osamu Miyazaki ,  Takashi Kadowaki ,  Toshimasa Yamauchi ,  Kazuo Hara

    IPC分类号： G01N33/53 ,  C12Q1/37

    CPC分类号： G01N33/74 ,  G01N2800/042 ,  G01N2800/32

    摘要： We have discovered a “human adiponectin ELISA kit”, which can specifically measure adiponectin in human blood serum (or blood plasma) or in extracted fluid from lipocytes or culture supernatant fluid. After fractioning human serum by use of gel filtration column, each fraction was measured by the present kit, and as a result, adiponectin immunity activity was detected as a plurality of peaks at above 670 kD of molecular weight. From the results, it is presumed that adiponectin is present in the blood as a polymer or forms a complex with polymer proteins.

    摘要翻译： 我们已经发现了一种“人类脂联素ELISA试剂盒”，可以特异性地测量人血清（或血浆）中的脂联素或来自脂肪细胞或培养上清液的提取液。 通过使用凝胶过滤柱对人血清进行分馏后，通过本试剂盒测定各级分，结果，在670kD以上的分子量下检测出多个峰的脂联素免疫活性。 从结果可以推测，脂联素作为聚合物存在于血液中，或与聚合物蛋白形成复合物。